Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Choline C-11

FDA-approved product (injectable, intravenous), marketed as Choline C-11.

Registered studies
27
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Choline C-11
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Prostate adenocarcinoma
  • Prostate cancer

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Choline C-11, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA11.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli5.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis17.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

27registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
  • E. coli: measured active in 0 of 1 lab record
Open Choline C-11 in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-3.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-3.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Choline C-11 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

    NCT02260817 · start 2014-10

    Registered record
    Registry ID
    NCT02260817
    Conditions
    Metastatic Prostate Cancer
    Interventions
    11C-choline Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2018-06
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    Intervention11C-choline Injection
    PhasePhase 3
    Registry statusCompleted

  • Assessment of Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure Without Androgen Deprivation Therapy

    NCT06167824 · start 2014-06-19

    Registered record
    Registry ID
    NCT06167824
    Conditions
    Prostate Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-06-19
    Completion
    2014-07-15
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland

    NCT02004418 · start 2014-03

    Registered record
    Registry ID
    NCT02004418
    Conditions
    Prostatic Neoplasms
    Interventions
    11C-Choline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2020-09
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    Intervention11C-Choline
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure.

    NCT06168890 · start 2014-02-04

    Registered record
    Registry ID
    NCT06168890
    Conditions
    Prostate Cancer
    Interventions
    PET/CT with choline in the restaging phase of prostate cancer.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-02-04
    Completion
    2014-02-25
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPET/CT with choline in the restaging phase of prostate cancer.
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma

    NCT01377220 · start 2011-06

    Registered record
    Registry ID
    NCT01377220
    Conditions
    Hepatocellular Carcinoma
    Interventions
    11C-Choline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-06
    Completion
    2014-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    Intervention11C-Choline
    PhasePhase 2
    Registry statusUnknown

  • Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma

    NCT01221896 · start 2011-01

    Registered record
    Registry ID
    NCT01221896
    Conditions
    Hyperparathyroidism
    Interventions
    C11-Choline PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperparathyroidism
    InterventionC11-Choline PET/CT
    PhaseNot recorded
    Registry statusUnknown

  • Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer

    NCT01132599 · start 2010-05

    Registered record
    Registry ID
    NCT01132599
    Conditions
    Prostate Cancer
    Interventions
    C-11 choline; 18F-fluoromethylcholine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2010-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionC-11 choline; 18F-fluoromethylcholine
    PhasePhase 2
    Registry statusWithdrawn

  • A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer

    NCT01051479 · start 2010-03

    Registered record
    Registry ID
    NCT01051479
    Conditions
    Esophageal Cancer
    Interventions
    C11-Choline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2013-08
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer
    InterventionC11-Choline
    PhasePhase 1
    Registry statusCompleted

  • C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer

    NCT00804245 · start 2008-08

    Registered record
    Registry ID
    NCT00804245
    Conditions
    Prostate Cancer
    Interventions
    needle biopsy; PET-CT scans supplemented with 11C-Choline tracer
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2013-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionneedle biopsy; PET-CT scans supplemented with 11C-Choline tracer
    PhasePhase 1
    Registry statusCompleted

  • Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration

    NCT00987376 · start 2003-11

    Registered record
    Registry ID
    NCT00987376
    Conditions
    Prostate Cancer
    Interventions
    Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-11
    Completion
    2009-09
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDiagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy
    PhasePhase 1
    Registry statusCompleted

  • Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study

    NCT02355054

    Registered record
    Registry ID
    NCT02355054
    Conditions
    Cancer of the Prostate
    Interventions
    C-11 Choline PET Imaging
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of the Prostate
    InterventionC-11 Choline PET Imaging
    PhaseNot recorded
    Registry statusApproved for marketing

  • Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

    NCT02531672

    Registered record
    Registry ID
    NCT02531672
    Conditions
    Prostate Cancer; Recurrent Prostate Cancer
    Interventions
    11C-choline; PET/CT Scan
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Recurrent Prostate Cancer
    Intervention11C-choline; PET/CT Scan
    PhaseNot recorded
    Registry statusNo longer available